top of page


Teva secures US commercialisation rights to two Samsung Bioepis immunology biosimilars in deal worth up to $420 million
Teva has secured US commercialisation rights to two FDA-approved Samsung Bioepis immunology biosimilars under an agreement worth up to $420 million, expanding its specialty biologics portfolio.

nuaxia
Nov 42 min read


Celltrion licenses Kaigene anti-APRIL antibody KG013 for up to $580.5 million
Celltrion has licensed Kaigene's next-generation anti-APRIL antibody KG013 in a global agreement worth up to $580.5 million plus royalties.

nuaxia
Oct 232 min read


FDA approves Lisraya as first oral treatment for adults with dermatomyositis
Priovant’s once-daily JAK/TYK2 inhibitor introduces a new FDA-approved treatment option for the rare autoimmune disease, supported by Phase III evidence of improvements across muscle, skin and physical-function measures.

nuaxia
Aug 282 min read


CDSCO approves Dr Reddy’s abatacept biosimilar for rheumatoid and psoriatic arthritis in India
The conditional marketing approval introduces a new intravenous abatacept biosimilar for patients with moderate to severe rheumatoid arthritis or active psoriatic arthritis who have responded inadequately to other disease-modifying treatments.

nuaxia
Aug 262 min read


FDA approves Imaavy as first treatment specifically indicated for warm autoimmune haemolytic anaemia
The approval extends Johnson & Johnson’s FcRn-blocking therapy into wAIHA, providing a new targeted treatment for adults with a rare autoimmune blood disorder that can cause severe and persistent haemolytic anaemia.

nuaxia
Aug 252 min read


FDA approves Reditux as rituximab biosimilar for B-cell malignancies and autoimmune diseases
The approval adds another US biosimilar option for rituximab-treated conditions, including non-Hodgkin lymphoma and chronic lymphocytic leukaemia, although commercial availability and pricing have not yet been confirmed.

nuaxia
Aug 62 min read
bottom of page